Business
Cardiol Therapeutics Reports 2020 AGM Results
Oakville, Ontario--(Newsfile Corp. - June 2, 2020) - Cardiol Therapeutics Inc. ( TSX: CRDL) ...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Reports 2020 AGM ResultsOakville, Ontario--(Newsfile Corp. - June 2, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (\"Cardiol\" or the \"Company\"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, announces results from its Annual General Meeting (\"AGM\") of shareholders held in Toronto, Ontario, on June 1, 2020. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.Resolutions proposed and approved at the AGM are:The re-election of the following directors for the ensuing year: David Elsley, Dr. Eldon R. Smith, Deborah Brown, Iain Chalmers, Peter Pekos, Dr. Guillermo Torre-Amione, Colin Stott.The appointment of BDO Canada LLP as auditors of the Company until the next annual meeting and the authorization of the directors of the Company to fix the remuneration to be paid to the auditors.The approval of the Company's Amended and Restated Equity Compensation Plan.The results of the voting on the election of directors are as follows:NomineesNumber of Shares ForPercentage of Votes CastDavid Elsley9,609,58298.77%Dr. Eldon R. Smith9,609,83798.77%  Deborah Brown9,721,335 99.92% Iain Chalmers 9,602,021 98.69% Peter Pekos 9,600,771  98.68% Dr. Guillermo Torre-Amione 9,728,57299.99% Colin Stott 9,719,91199.90% About Cardiol TherapeuticsCardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is focused on producing pharmaceutical cannabidiol (CBD) products and developing innovative therapies for heart diseases, including acute myocarditis and other causes of heart failure. The Company's lead product, CardiolRx™, is formulated to be the most consistent cannabidiol formulation on the market. CardiolRx is pharmaceutically produced, manufactured under cGMP, and is THC free (<5 ppm). The Company also plans to commercialize CardiolRx in the billion-dollar market for medicinal cannabinoids in Canada and is pursuing distribution opportunities in Europe and Latin America.In heart failure, Cardiol is planning an international clinical study of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company i...